Stock Events

Stock Events

Tryp Therapeutics 

$0.06
13
+$0.01+32.24% Wednesday 21:17

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14DecExpected
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
-0.04
-0.03
-0.01
0
Expected EPS
N/A
Actual EPS
-0.0175

Financials

-Profit Margin
Profitable
2021
2022
2023
0Revenue
2,725.4Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TRYPF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap606.35M
Compass Pathways focuses on psilocybin therapy for depression, directly competing in the psychedelic medicine space with Tryp Therapeutics' focus on disorders with unmet medical needs.
AtaiBeckley
ATAI
Mkt Cap1.56B
ATAI Life Sciences is a biotech company developing psychedelic and non-psychedelic compounds for mental health disorders, competing in the same space as Tryp.
Cybin Inc
CYBN
Mkt Cap200.49M
Cybin Inc. works on psychedelic therapeutics for psychiatric and neurological conditions, directly competing with Tryp's focus areas.
GH Research
GHRS
Mkt Cap888.26M
GH Research is developing a novel therapeutic approach for mental health disorders using psychedelics, aligning with Tryp's mission.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including mental health treatments, competing with Tryp's objectives.
Revive Therapeutics
RVVTF
Mkt Cap4.68M
Revive Therapeutics explores the use of psychedelics for treatments in various diseases, including areas of interest for Tryp.
Noveris Health Sciences
MYCOF
Mkt Cap14.59M
Mydecine Innovations Group is engaged in the development of psychedelic compounds for mental health and addiction, similar to Tryp's focus.

About

Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.
Show more...
CEO
Country
CA
ISIN
CA89854F1062
WKN
000A2QKZP

Listings

0 Comments

Share your thoughts

FAQ

What is Tryp Therapeutics stock price today?▼
The current price of TRYPF is $0.06 USD — it has increased by +32.24% in the past 24 hours. Watch Tryp Therapeutics stock price performance more closely on the chart.
What is Tryp Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tryp Therapeutics stocks are traded under the ticker TRYPF.
What were Tryp Therapeutics earnings last quarter?▼
TRYPF earnings for the last quarter are -0.02 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tryp Therapeutics revenue for the last year?▼
Tryp Therapeutics revenue for the last year amounts to 0 USD.
What is Tryp Therapeutics net income for the last year?▼
TRYPF net income for the last year is 2,725.4 USD.
In which sector is Tryp Therapeutics located?▼
Tryp Therapeutics operates in the Professional, Scientific, and Technical Services sector.
When did Tryp Therapeutics complete a stock split?▼
Tryp Therapeutics has not had any recent stock splits.